ATE429493T1 - An akt2 bindendesprotein - Google Patents

An akt2 bindendesprotein

Info

Publication number
ATE429493T1
ATE429493T1 AT03777257T AT03777257T ATE429493T1 AT E429493 T1 ATE429493 T1 AT E429493T1 AT 03777257 T AT03777257 T AT 03777257T AT 03777257 T AT03777257 T AT 03777257T AT E429493 T1 ATE429493 T1 AT E429493T1
Authority
AT
Austria
Prior art keywords
aforementioned
improving agent
screening
insulin resistance
carbohydrate metabolism
Prior art date
Application number
AT03777257T
Other languages
English (en)
Inventor
Yuki Endo
Hideki Endoh
Yoshitaka Ueda
Miyuki Kato
Kazunori Inabe
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE429493T1 publication Critical patent/ATE429493T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
AT03777257T 2002-12-05 2003-12-04 An akt2 bindendesprotein ATE429493T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002354155 2002-12-05
JP2003206952 2003-08-08
PCT/JP2003/015546 WO2004050869A1 (ja) 2002-12-05 2003-12-04 Akt2に結合する蛋白質

Publications (1)

Publication Number Publication Date
ATE429493T1 true ATE429493T1 (de) 2009-05-15

Family

ID=32473704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03777257T ATE429493T1 (de) 2002-12-05 2003-12-04 An akt2 bindendesprotein

Country Status (9)

Country Link
US (1) US7452983B2 (de)
EP (1) EP1568768B1 (de)
JP (1) JP4438951B2 (de)
AT (1) ATE429493T1 (de)
AU (1) AU2003289186A1 (de)
CA (1) CA2508232A1 (de)
DE (1) DE60327361D1 (de)
ES (1) ES2324779T3 (de)
WO (1) WO2004050869A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD629025S1 (en) * 2008-03-27 2010-12-14 Greenleaf Richard J Shedder pin
TWD137060S1 (zh) * 2009-07-06 2010-09-21 Smc股份有限公司 空氣壓機器用消音器
CN111718898B (zh) * 2020-07-06 2021-01-15 北京智能宝生物科技有限公司 提高滑膜间充质干细胞逆境耐受性的方法及其试剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293569A3 (de) 2001-09-14 2004-03-31 Research Association for Biotechnology Vollständige cDNA-Sequenzen
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長cDNA
US20030181366A1 (en) * 2002-03-21 2003-09-25 Yan Luo Peptide inhibitors of Akt and uses thereof

Also Published As

Publication number Publication date
JPWO2004050869A1 (ja) 2006-03-30
AU2003289186A1 (en) 2004-06-23
EP1568768A4 (de) 2006-06-07
DE60327361D1 (de) 2009-06-04
AU2003289186A8 (en) 2004-06-23
WO2004050869A1 (ja) 2004-06-17
ES2324779T3 (es) 2009-08-14
WO2004050869A8 (ja) 2004-08-05
CA2508232A1 (en) 2004-06-17
JP4438951B2 (ja) 2010-03-24
US20060211041A1 (en) 2006-09-21
US7452983B2 (en) 2008-11-18
EP1568768A1 (de) 2005-08-31
EP1568768B1 (de) 2009-04-22

Similar Documents

Publication Publication Date Title
WO2005003172A3 (en) Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
SG158158A1 (en) Glp-1 agonists, compositions, methods and uses
SG161234A1 (en) A method and composition for nutritionally improving glucose control and insulin action
PT1067843E (pt) Formulacao para o melhoramento do metabolismo da glucose e da insulina em animais de companhia
BRPI0410884A (pt) composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação
BR0316564A (pt) Forma de dosagem de alérgeno
ATE446313T1 (de) Muteine von tränen-lipocalin
MX344559B (es) Compuestos de hormona de crecimiento humana recombinante unidos al peg.
DE69028448D1 (de) Herstellung von Hämoglobin und Analogen davon durch Bakterien oder Hefen
EP1676488A3 (de) Verfahren und Verbindungen zur Kontrolle des Körpergewichts
ATE421314T1 (de) Verwendung eines kreuzblütler-proteinhydrolysats als depigmentierungsmittel oder für eine kosmetische und/oder pharmazeutische zusammensetzung
EA200600996A1 (ru) Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма
YU66892A (sh) Fosfoinositolglikan - peptid sa delovanjem kao insulin
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
DE60327361D1 (de) An akt2 bindendesprotein
ATE457129T1 (de) Mehrkomponentenfutter für katzen
ATE403725T1 (de) Cap-bindungsprotein
DE502005009568D1 (de) Pharmazeutische Zubereitungen als Hydrogel, die Diaminooxidase enthalten
ATE473752T1 (de) Verwendung von verbindungen zur induktion der synthese von sirt-proteinen bei der oder für die herstellung eines kosmetikums oder einer pharmazeutischen zusammensetzung
WO2007050178A3 (en) Skin care composition for accelerated production of collagen proteins and method of fabricating same
ATE510009T1 (de) Förderung der peroxisomalenkatalasefunktion in zellen
DE602004025212D1 (de) Pulverförmige zusammensetzungen von fettlöslichen substanzen
CN105535025A (zh) 嫩肤美白营养液及嫩肤美白组合物
CN102940602A (zh) 一种美肌精华粉
DE60122701D1 (de) Kosmetische oder dermatologische cremezubereitung, deren herstellung und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties